A comparison of factors that influence survival in dogs with adrenal-dependent hyperadrenocorticism treated with mitotane or trilostane.

Helm, J R; McLauchlan, G; Boden, L A; Frowde, P E; Collings, A J; Tebb, A J; Elwood, C M; Herrtage, M E; Parkin, T D H; Ramsey, I K

Helm, J R; McLauchlan, G; Boden, L A; Frowde, P E; Collings, A J; Tebb, A J; Elwood, C M; Herrtage, M E; Parkin, T D H; Ramsey, I K.

Affiliation

Helm JR; School of Veterinary Medicine, University of Glasgow, Glasgow, UK. jenny.helm@glasgow.ac.uk

J Vet Intern Med ; 25(2): 251-60, 2011.

Article in En | MEDLINE | ID: mdl-21352377

Subject(s)

Adrenocortical Hyperfunction/veterinary; Antineoplastic Agents, Hormonal/therapeutic use; Dihydrotestosterone/analogs & derivatives; Dog Diseases/drug therapy; Mitotane/therapeutic use; Adrenocortical Hyperfunction/drug therapy; Adrenocortical Hyperfunction/mortality; Animals; Dihydrotestosterone/therapeutic use; Dog Diseases/mortality; Dogs; Drug Therapy, Combination; Female; Male; Retrospective Studies; Survival Analysis; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Dihydrotestosterone / Adrenocortical Hyperfunction / Antineoplastic Agents, Hormonal / Dog Diseases / Mitotane Type of study: Observational_studies / Risk_factors_studies Limits: Animals Language: En Year: 2011 Type: Article

Fulltext

XML

PubMed Links

Search on Google